Canfosfamide
Alternative Names: Telcyta; TER 286; TLK 286Latest Information Update: 10 Jul 2013
At a glance
- Originator Telik
- Class Antineoplastics; Oligopeptides; Small molecules
- Mechanism of Action Glutathione transferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer
- Discontinued Breast cancer; Colorectal cancer
Most Recent Events
- 10 Jul 2013 Canfosfamide is still available for licensing. http://www.telik.com
- 05 Apr 2013 Telik terminates phase II trial in Diffuse large B cell lymphoma, Mantle cell lymphoma and Multiple myeloma in the USA (NCT01148108)
- 31 Mar 2013 Suspended - Phase-II for Diffuse large B cell lymphoma in USA (IV)